Clinical Trial Update: Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS [Phase 2]

View source ↗

Summary

Phase 2 open-label, multi-dose study of Panhematin in patients with myelodysplastic syndrome was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Panhematin (heme arginate (hemin))

Snippet

Sponsor: Rush University Medical Center | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2014-10-24